Skip Navigation
Skip to contents

Journal of Microbiology : Journal of Microbiology

OPEN ACCESS
SEARCH
Search

Previous issues

Page Path
HOME > Browse Articles > Previous issues
12 Previous issues
Filter
Filter
Article category
Keywords
Volume 60(3); March 2022
Prev issue Next issue
Editorial
[SPECIAL ISSUE]Two years of COVID-19 pandemic: where are we now?
Jinjong Myoung
J. Microbiol. 2022;60(3):235-237.
DOI: https://doi.org/10.1007/s12275-022-1679-x
  • 57 View
  • 0 Download
  • 15 Web of Science
  • 12 Crossref

Citations

Citations to this article as recorded by  
  • Real-time infectious disease endurance indicator system for scientific decisions using machine learning and rapid data processing
    Shivendra Dubey, Dinesh Kumar Verma, Mahesh Kumar
    PeerJ Computer Science.2024; 10: e2062.     CrossRef
  • Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications
    Isa Seida, Mahmoud Alrais, Ravend Seida, Abdulkarim Alwani, Zeynep Kiyak, Abdulrahman Elsalti, Sevval Nil Esirgun, Tunahan Abali, Naim Mahroum
    Clinical and Experimental Immunology.2023; 213(1): 87.     CrossRef
  • Surgical Treatment of Another Sequalae of COVID-19: Post-COVID CTEPH
    Nezih Onur Ermerak, Sehnaz Olgun Yildizeli, Derya Kocakaya, Bulent Mutlu, Koray Ak, Serpil Tas, Bedrettin Yildizeli
    The Thoracic and Cardiovascular Surgeon.2023; 71(05): 413.     CrossRef
  • Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
    Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
    Journal of Microbiology and Biotechnology.2023; 33(12): 1587.     CrossRef
  • Paxlovid for Treating COVID-19 Patients: A Case-Control Study From Two Hospitals in the Eastern Province of Saudi Arabia
    Ali Alsaeed, Abdullah Alkhalaf, Ali Alomran, Walaa Alsfyani, Fadhel Alhaddad, Mousa J Alhaddad
    Cureus.2023;[Epub]     CrossRef
  • Ethical and coordinative challenges in setting up a national cohort study during the COVID-19 pandemic in Germany
    Katharina Tilch, Sina M. Hopff, Katharina Appel, Monika Kraus, Bettina Lorenz-Depiereux, Lisa Pilgram, Gabi Anton, Sarah Berger, Ramsia Geisler, Kirsten Haas, Thomas Illig, Dagmar Krefting, Roberto Lorbeer, Lazar Mitrov, Maximilian Muenchhoff, Matthias Na
    BMC Medical Ethics.2023;[Epub]     CrossRef
  • Impact of the COVID-19 pandemic on the conduct of non-COVID-19 clinical trials: protocol for a scoping review
    Wenru Shang, Lili Wei, Yujia Liu, Haosheng Pu, Xiuxia Li, Junqiang Niu, Long Ge, Cuncun Lu, Kehu Yang
    BMJ Open.2023; 13(10): e074128.     CrossRef
  • Amiodarone for the Treatment of Arrhythmias in COVID-19 Patients Does Not Increase the Risk of Pulmonary Fibrosis: A Retrospective Cohort Study
    David B Money, Dae Hyun Lee, Ari Hadar, Justin Doherty, Christopher Malanga, Alexa Serino, Adam J Cohen
    Cureus.2023;[Epub]     CrossRef
  • Loyalty in the time of COVID-19: A review of the literature in tourism destination settings
    Oliver Cruz-Milán
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • Challenges of rapamycin repurposing as a potential therapeutic candidate for COVID-19: implications for skeletal muscle metabolic health in older persons
    Matthew J. Lees, Nathan Hodson, Cassidy T. Tinline-Goodfellow, Hugo J. W. Fung, Antonis Elia, Daniel R. Moore
    American Journal of Physiology-Endocrinology and Metabolism.2022; 322(6): E551.     CrossRef
  • Use of Alcohol, Cannabinoids, Psychostimulants, and Sedatives before and during the COVID-19 Pandemic among Students in 40 European Countries
    Mateusz Babicki
    International Journal of Environmental Research and Public Health.2022; 19(22): 14879.     CrossRef
  • Evaluation of Vaccine Hesitancy and Anxiety Levels among Hospital Cleaning Staff and Caregivers during COVID-19 Pandemic
    Sami Akbulut, Ayse Gokce, Gulseda Boz, Hasan Saritas, Selver Unsal, Ali Ozer, Mehmet Serdar Akbulut, Cemil Colak
    Vaccines.2022; 10(9): 1426.     CrossRef
Reviews
Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies
Jung-ah Choi , Jae-Ouk Kim
J. Microbiol. 2022;60(3):238-246.   Published online January 28, 2022
DOI: https://doi.org/10.1007/s12275-022-1547-8
  • 64 View
  • 0 Download
  • 10 Web of Science
  • 6 Crossref
AbstractAbstract
Middle East Respiratory Syndrome coronavirus (MERS-CoV), a contagious zoonotic virus, causes severe respiratory infection with a case fatality rate of approximately 35% in humans. Intermittent sporadic cases in communities and healthcare facility outbreaks have continued to occur since its first identification in 2012. The World Health Organization has declared MERS-CoV a priority pathogen for worldwide research and vaccine development due to its epidemic potential and the insufficient countermeasures available. The Coalition for Epidemic Preparedness Innovations is supporting vaccine development against emerging diseases, including MERS-CoV, based on platform technologies using DNA, mRNA, viral vector, and protein subunit vaccines. In this paper, we review the usefulness and structure of a spike glycoprotein as a MERSCoV vaccine candidate molecule, and provide an update on the status of MERS-CoV vaccine development. Vaccine candidates based on both DNA and viral vectors coding MERSCoV spike gene have completed early phase clinical trials. A harmonized approach is required to assess the immunogenicity of various candidate vaccine platforms. Platform technologies accelerated COVID-19 vaccine development and can also be applied to developing vaccines against other emerging viral diseases.

Citations

Citations to this article as recorded by  
  • Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies
    Chamandi S. Dampalla, Yunjeong Kim, Alexandria Zabiegala, Dennis J. Howard, Harry Nhat Nguyen, Trent K. Madden, Hayden A. Thurman, Anne Cooper, Lijun Liu, Kevin P. Battaile, Scott Lovell, Kyeong-Ok Chang, William C. Groutas
    Journal of Medicinal Chemistry.2024; 67(14): 11937.     CrossRef
  • Role of vaccination in patients with human monkeypox virus and its cardiovascular manifestations
    Khawaja Usama Maqbool, Muhammad Talha Akhtar, Shayan Ayub, FNU Simran, Jahanzeb Malik, Maria Malik, Rafia Zubair, Amin Mehmoodi
    Annals of Medicine & Surgery.2024; 86(3): 1506.     CrossRef
  • The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS – a critical overview
    Hans-Gert Bernstein, Gerburg Keilhoff, Henrik Dobrowolny, Johann Steiner
    Reviews in the Neurosciences.2023; 34(1): 1.     CrossRef
  • MERS-CoV recently re-emerged in Qatar, Saudi Arabia, its feasible global health risks amid FIFA world cup 2022 and salient counteracting strategies – an update
    Hitesh Chopra, Md. Aminul Islam, Deepak Chandran, Talha B. Emran, Nahed A. El-Shall, Jaffar A. Al-Tawfiq, Kuldeep Dhama
    International Journal of Surgery.2023; 109(2): 153.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
  • Comparing the Immunogenicity and Protective Effects of Three MERS-CoV Inactivation Methods in Mice
    Nayoung Kim, Tae-Young Lee, Hansaem Lee, Jeong-Sun Yang, Kyung-Chang Kim, Joo-Yeon Lee, Hyun-Joo Kim
    Vaccines.2022; 10(11): 1843.     CrossRef
Current status and perspectives on vaccine development against dengue virus infection
Jisang Park , Ju Kim , Yong-Suk Jang
J. Microbiol. 2022;60(3):247-254.   Published online February 14, 2022
DOI: https://doi.org/10.1007/s12275-022-1625-y
  • 134 View
  • 0 Download
  • 29 Web of Science
  • 28 Crossref
AbstractAbstract
Dengue virus (DENV) consists of four serotypes in the family Flaviviridae and is a causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. DENV is transmitted by mosquitoes, Aedes aegypti and A. albopictus, and is mainly observed in areas where vector mosquitoes live. The number of dengue cases reported by the World Health Organization increased more than 8-fold over the last two decades from 505,430 in 2000 to over 2.4 million in 2010 to 5.2 million in 2019. Although vaccine is the most effective
method
against DENV, only one commercialized vaccine exists, and it cannot be administered to children under 9 years of age. Currently, many researchers are working to resolve the various problems hindering the development of effective dengue vaccines; understanding of the viral antigen configuration would provide insight into the development of effective vaccines against DENV infection. In this review, the current status and perspectives on effective vaccine development for DENV are examined. In addition, a plausible direction for effective vaccine development against DENV is suggested.

Citations

Citations to this article as recorded by  
  • Stochastic Runge–Kutta for numerical treatment of dengue epidemic model with Brownian uncertainty
    Nabeela Anwar, Iftikhar Ahmad, Hijab Javaid, Adiqa Kausar Kiani, Muhammad Shoaib, Muhammad Asif Zahoor Raja
    Modern Physics Letters B.2025;[Epub]     CrossRef
  • Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody
    Supaluk Krittanai, Kaewta Rattanapisit, Christine Joy I. Bulaon, Pannamthip Pitaksajjakul, Sujitra Keadsanti, Pongrama Ramasoota, Richard Strasser, Waranyoo Phoolcharoen
    Biotechnology Reports.2024; 42: e00844.     CrossRef
  • In silico strategies for predicting therapeutic peptides targeting the capsid protein of the dengue virus
    Neeraj Kumar Dixit, Ajay Kumar
    Journal of Proteins and Proteomics.2024; 15(4): 675.     CrossRef
  • Epidemiologic and clinical updates on viral infections in Saudi Arabia
    Noura M. Alshiban, Munirah S. Aleyiydi, Majed S. Nassar, Nada K. Alhumaid, Thamer A. Almangour, Yahya M.K. Tawfik, Laila A. Damiati, Abdulaziz S. Almutairi, Essam A. Tawfik
    Saudi Pharmaceutical Journal.2024; 32(7): 102126.     CrossRef
  • “Seven-Plus-One Model”: A Move Toward Dengue Free Community
    Santosh Kumar, Rakhi Mishra, Dharnidhar Singh
    Indian Journal of Community Medicine.2024; 49(2): 249.     CrossRef
  • Dengue fever: a decade of burden in Iran
    Zahra Heydarifard, Fatemeh Heydarifard, Fatemeh Sadat Mousavi, Milad Zandi
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • All-Atom Perspective of the DENV-3 Methyltransferase Inhibition Mechanism
    Xiao Liu, Kaiwen Pang, Hangfei Wu, Xiaohui Wang, John Z. H. Zhang, Zhaoxi Sun
    The Journal of Physical Chemistry B.2024; 128(50): 12358.     CrossRef
  • Using UAV images and deep learning in investigating potential breeding sites of Aedes albopictus
    Keyi Yu, Jianping Wu, Minghao Wang, Yizhou Cai, Minhui Zhu, Shenjun Yao, Yibin Zhou
    Acta Tropica.2024; 255: 107234.     CrossRef
  • Dengue
    Gabriela Paz-Bailey, Laura E Adams, Jacqueline Deen, Kathryn B Anderson, Leah C Katzelnick
    The Lancet.2024; 403(10427): 667.     CrossRef
  • Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) as a Novel Score in Early Detection of Complicated Dengue Fever
    Zubia Jamil, Samreen Khalid, Hafiz Muhammad Khan, Ikram Waheed, Amna Ehsan, Mohammed Alissa, Khalid Muhammad, Nayla Munawar, Yasir Waheed
    Journal of Multidisciplinary Healthcare.2024; Volume 17: 2321.     CrossRef
  • Dengue Virus 2 NS2B Targets MAVS and IKKε to Evade the Antiviral Innate Immune Response
    Ying Nie, Dongqing Deng, Lumin Mou, Qizhou Long, Jinzhi Chen, Jiahong Wu
    Journal of Microbiology and Biotechnology.2023; 33(5): 600.     CrossRef
  • Deep learning approach for detection of Dengue fever from the microscopic images of blood smear
    Hilda Mayrose, Niranjana Sampathila, G Muralidhar Bairy, Tushar Nayak, Sushma Belurkar, Kavitha Saravu
    Journal of Physics: Conference Series.2023; 2571(1): 012005.     CrossRef
  • Analysis of the correlation between climatic variables and Dengue cases in the city of Alagoinhas/BA
    Marcos Batista Figueredo, Roberto Luiz Souza Monteiro, Alexandre do Nascimento Silva, José Roberto de Araújo Fontoura, Andreia Rita da Silva, Carolina Aparecida Pereira Alves
    Scientific Reports.2023;[Epub]     CrossRef
  • Dengue overview: An updated systemic review
    Muhammad Bilal Khan, Zih-Syuan Yang, Chih-Yen Lin, Ming-Cheng Hsu, Aspiro Nayim Urbina, Wanchai Assavalapsakul, Wen-Hung Wang, Yen-Hsu Chen, Sheng-Fan Wang
    Journal of Infection and Public Health.2023; 16(10): 1625.     CrossRef
  • Applying a multi-strain dengue model to epidemics data
    Robert G.S. de Araújo, Daniel C.P. Jorge, Rejane C. Dorn, Gustavo Cruz-Pacheco, M. Lourdes M. Esteva, Suani T.R. Pinho
    Mathematical Biosciences.2023; 360: 109013.     CrossRef
  • Impact of bound ssRNA length on allostery in the Dengue Virus NS3 helicase
    Fernando Amrein, Carolina Sarto, Leila A Cababie, F Luis Gonzalez Flecha, Sergio B Kaufman, Mehrnoosh Arrar
    Nucleic Acids Research.2023; 51(20): 11213.     CrossRef
  • A novel colorimetric biosensor for rapid detection of dengue virus upon acid-induced aggregation of colloidal gold
    Vo Thi Cam Duyen, Vo Van Toi, Truong Van Hoi, Phuoc Long Truong
    Analytical Methods.2023; 15(32): 3991.     CrossRef
  • Aromatic Residues on the Side Surface of Cry4Ba-Domain II of Bacillus thuringiensis subsp. israelensis Function in Binding to Their Counterpart Residues on the Aedes aegypti Alkaline Phosphatase Receptor
    Anon Thammasittirong, Sutticha Na-Ranong Thammasittirong
    Toxins.2023; 15(2): 114.     CrossRef
  • Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus
    Ju Kim, Tae Young Lim, Jisang Park, Yong-Suk Jang
    Journal of Microbiology.2023; 61(1): 131.     CrossRef
  • Prevalence of dengue fever in Saudi Arabia: Jeddah as a case study
    Hanan S. Alyahya
    Entomological Research.2023; 53(12): 539.     CrossRef
  • Biological Functions and Utilization of Different Part of the Papaya: A Review
    Mingyue Jiao, Chao Liu, M.A. Prieto, Xiaoming Lu, Wenfu Wu, Jinyue Sun, P. García-Oliveira, Xiaozhen Tang, Jianbo Xiao, Jesus Simal-Gandara, Dagang Hu, Ningyang Li
    Food Reviews International.2023; 39(9): 6781.     CrossRef
  • Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
    Li-Chen Yen, Hsin-Wei Chen, Chia-Lo Ho, Chang-Chi Lin, Yi-Ling Lin, Qiao-Wen Yang, Kuo-Chou Chiu, Shu-Pei Lien, Ren-Jye Lin, Ching-Len Liao
    Journal of Biomedical Science.2023;[Epub]     CrossRef
  • Dengue hemorrhagic fever: a growing global menace
    Shakeela Parveen, Zainab Riaz, Saba Saeed, Urwah Ishaque, Mehwish Sultana, Zunaira Faiz, Zainab Shafqat, Saman Shabbir, Sana Ashraf, Amna Marium
    Journal of Water and Health.2023; 21(11): 1632.     CrossRef
  • Exploring the inhibitory potential of Nigella sativa against dengue virus NS2B/NS3 protease and NS5 polymerase using computational approaches
    Mamuna Mukhtar, Haris Ahmed Khan, Najam us Sahar Sadaf Zaidi
    RSC Advances.2023; 13(27): 18306.     CrossRef
  • Scratching the Surface Takes a Toll: Immune Recognition of Viral Proteins by Surface Toll-like Receptors
    Alexis A. Hatton, Fermin E. Guerra
    Viruses.2022; 15(1): 52.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
  • Predictors of complicated dengue infections in endemic region of Pakistan
    Ikram Waheed, Samreen Khalid, Zubia Jamil
    Asian Pacific Journal of Tropical Medicine.2022; 15(11): 496.     CrossRef
  • Engineering Modified mRNA-Based Vaccine against Dengue Virus Using Computational and Reverse Vaccinology Approaches
    Mamuna Mukhtar, Amtul Wadood Wajeeha, Najam us Sahar Sadaf Zaidi, Naseeha Bibi
    International Journal of Molecular Sciences.2022; 23(22): 13911.     CrossRef
Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models
Young-Il Kim , Mark Anthony B. Casel , Young Ki Choi
J. Microbiol. 2022;60(3):255-267.   Published online March 2, 2022
DOI: https://doi.org/10.1007/s12275-022-2033-z
  • 61 View
  • 0 Download
  • 11 Web of Science
  • 9 Crossref
AbstractAbstract
As of February 2022, SARS-CoV-2 is still one of the most serious public health threats due to its high mortality rate and rapid spread of novel variants. Since the first outbreak in 2019, general understanding of SARS-CoV-2 has been improved through basic and clinical studies; however, knowledge gaps still exist in our understanding of the emerging novel SARSCoV- 2 variants, which impacts the corresponding development of vaccines and therapeutics. Especially, accumulation of mutations in SARS-CoV-2 and rapid spread in populations with previous immunity has resulted in selection of variants that evade the host immune response. This phenomenon threatens to render current SARS-CoV-2 vaccines ineffective for controlling the pandemic. Proper animal models are essential for detailed investigations into the viral etiology, transmission and pathogenesis mechanisms, as well as evaluation of the efficacy of vaccine candidates against recent SARS-CoV-2 variants. Further, the choice of animal model for each research topic is important for researchers to gain better knowledge of recent SARS-CoV-2 variants. Here, we review the advantages and limitations of each animal model, including mice, hamsters, ferrets, and non-human primates, to elucidate variant SARS-CoV-2 etiology and transmission and to evaluate therapeutic and vaccine efficacy.

Citations

Citations to this article as recorded by  
  • In vivo characterization of ACE2 expression in Sprague-Dawley rats and cultured primary brain pericytes highlights the utility of Rattus norvegicus in the study of COVID-19 brain pathophysiology
    Eugene Park, Elaine Liu, Andrew J. Baker
    Brain Research.2025; 1848: 149333.     CrossRef
  • Utilizing non‐human primate models to combat recent COVID‐19/SARS‐CoV‐2 and viral infectious disease outbreaks
    Taeho Kwon
    Journal of Medical Primatology.2024;[Epub]     CrossRef
  • Early detection of highly transmissible viral variants using phylogenomics
    Michael R. May, Bruce Rannala
    Science Advances.2024;[Epub]     CrossRef
  • Animal Models, Zoonotic Reservoirs, and Cross-Species Transmission of Emerging Human-Infecting Coronaviruses
    Yakhouba Kane, Gary Wong, George F. Gao
    Annual Review of Animal Biosciences.2023; 11(1): 1.     CrossRef
  • SARS-CoV-2 Aerosol and Intranasal Exposure Models in Ferrets
    Elizabeth E. Zumbrun, Samantha E. Zak, Eric D. Lee, Philip A. Bowling, Sara I. Ruiz, Xiankun Zeng, Jeffrey W. Koehler, Korey L. Delp, Russel R. Bakken, Shannon S. Hentschel, Holly A. Bloomfield, Keersten M. Ricks, Tamara L. Clements, April M. Babka, John
    Viruses.2023; 15(12): 2341.     CrossRef
  • The Isolation and In Vitro Differentiation of Primary Fetal Baboon Tracheal Epithelial Cells for the Study of SARS-CoV-2 Host-Virus Interactions
    Bharathiraja Subramaniyan, Sunam Gurung, Manish Bodas, Andrew R. Moore, Jason L. Larabee, Darlene Reuter, Constantin Georgescu, Jonathan D. Wren, Dean A. Myers, James F. Papin, Matthew S. Walters
    Viruses.2023; 15(4): 862.     CrossRef
  • Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
    Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
    Journal of Microbiology and Biotechnology.2023; 33(12): 1587.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
  • SARS CoV-2 (Delta Variant) Infection Kinetics and Immunopathogenesis in Domestic Cats
    Miruthula Tamil Selvan, Sachithra Gunasekara, Ping Xiao, Kristen Griffin, Shannon R. Cowan, Sai Narayanan, Akhilesh Ramachandran, Darren E. Hagen, Jerry W. Ritchey, Jennifer M. Rudd, Craig A. Miller
    Viruses.2022; 14(6): 1207.     CrossRef
Protective and pathogenic role of humoral responses in COVID-19
Uni Park , Nam-Hyuk Cho
J. Microbiol. 2022;60(3):268-275.   Published online March 2, 2022
DOI: https://doi.org/10.1007/s12275-022-2037-8
  • 63 View
  • 0 Download
  • 5 Web of Science
  • 3 Crossref
AbstractAbstract
Since the advent of SARS-CoV-2 in Dec. 2019, the global endeavor to identify the pathogenic mechanism of COVID-19 has been ongoing. Although humoral immunity including neutralizing activity play an important role in protection from the viral pathogen, dysregulated antibody responses may be associated with the pathogenic progression of COVID-19, especially in high-risk individuals. In addition, SARS-CoV-2 spike-specific antibodies acquired by prior infection or vaccination act as immune pressure, driving continuous population turnover by selecting for antibody-escaping mutations. Here, we review accumulating knowledge on the potential role of humoral immune responses in COVID-19, primarily focusing on their beneficial and pathogenic properties. Understanding the multifaceted regulatory mechanisms of humoral responses during SARS-CoV-2 infection can help us to develop more effective therapeutics, as well as protective measures against the ongoing pandemic.

Citations

Citations to this article as recorded by  
  • Rise in broadly cross-reactive adaptive immunity against human β-coronaviruses in MERS-recovered patients during the COVID-19 pandemic
    So-Hee Kim, Yuri Kim, Sangeun Jeon, Uni Park, Ju-Il Kang, Kyeongseok Jeon, Hye-Ran Kim, Songhyeok Oh, Ji-Young Rhee, Jae-Phil Choi, Wan Beom Park, Sang Won Park, Jeong-Sun Yang, Joo-Yeon Lee, Jihye Kang, Hyoung-Shik Shin, Yeonjae Kim, Seungtaek Kim, Yeon-
    Science Advances.2024;[Epub]     CrossRef
  • Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
    Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
    Journal of Microbiology and Biotechnology.2023; 33(12): 1587.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
T cell responses to SARS-CoV-2 in humans and animals
Sameer-ul-Salam Mattoo , Jinjong Myoung
J. Microbiol. 2022;60(3):276-289.   Published online February 14, 2022
DOI: https://doi.org/10.1007/s12275-022-1624-z
  • 55 View
  • 0 Download
  • 10 Web of Science
  • 10 Crossref
AbstractAbstract
SARS-CoV-2, the causative agent of COVID-19, first emerged in 2019. Antibody responses against SARS-CoV-2 have been given a lot of attention. However, the armamentarium of humoral and T cells may have differing roles in different viral infections. Though the exact role of T cells in COVID-19 remains to be elucidated, prior experience with human coronavirus has revealed an essential role of T cells in the outcomes of viral infections. Moreover, an increasing body of evidence suggests that T cells might be effective against SARS-CoV-2. This review summarizes the role of T cells in mouse CoV, human pathogenic respiratory CoV in general and SARSCoV- 2 in specific.

Citations

Citations to this article as recorded by  
  • Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions
    Kuei-Ching Hsiung, Huan-Jung Chiang, Sebastian Reinig, Shin-Ru Shih
    Vaccines.2024; 12(12): 1345.     CrossRef
  • Intradermal Fractional ChAdOx1 nCoV-19 Booster Vaccine Induces Memory T Cells: A Follow-Up Study
    Ratchanon Sophonmanee, Perawas Preampruchcha, Jomkwan Ongarj, Bunya Seeyankem, Porntip Intapiboon, Smonrapat Surasombatpattana, Supattra Uppanisakorn, Pasuree Sangsupawanich, Sarunyou Chusri, Nawamin Pinpathomrat
    Vaccines.2024; 12(2): 109.     CrossRef
  • Safety and efficacy of COVID-19 vaccine immunization during pregnancy in 1024 pregnant women infected with the SARS-CoV-2 Omicron virus in Shanghai, China
    Hongmei Deng, Yinpeng Jin, Minmin Sheng, Min Liu, Jie Shen, Wei Qian, Gang Zou, Yixin Liao, Tiefu Liu, Yun Ling, Xiaohong Fan
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Differential Impact of Spike Protein Mutations on SARS-CoV-2 Infectivity and Immune Evasion: Insights from Delta and Kappa Variants
    Tae-Hun Kim, Sojung Bae, Jinjong Myoung
    Journal of Microbiology and Biotechnology.2024; 34(12): 2506.     CrossRef
  • Animal models for COVID-19 and tuberculosis
    Björn Corleis, Max Bastian, Donata Hoffmann, Martin Beer, Anca Dorhoi
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • A mathematical model and simulation scenarios for T and B cells immune response to severe acute respiratory syndrome-coronavirus-2
    L Cuesta-Herrera, F Córdova-Lepe, L Pastenes, A D Arencibia, Y Baldera-Moreno, H A Torres-Mantilla
    Journal of Physics: Conference Series.2023; 2516(1): 012007.     CrossRef
  • Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
    Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
    Journal of Microbiology and Biotechnology.2023; 33(12): 1587.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
  • Escape and Over-Activation of Innate Immune Responses by SARS-CoV-2: Two Faces of a Coin
    Sameer-ul-Salam Mattoo, Seong-Jun Kim, Dae-Gyun Ahn, Jinjong Myoung
    Viruses.2022; 14(3): 530.     CrossRef
  • Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector
    Irina Isakova-Sivak, Ekaterina Stepanova, Victoria Matyushenko, Sergei Niskanen, Daria Mezhenskaya, Ekaterina Bazhenova, Elena Krutikova, Tatiana Kotomina, Polina Prokopenko, Bogdan Neterebskii, Aleksandr Doronin, Elena Vinogradova, Kirill Yakovlev, Konst
    Vaccines.2022; 10(7): 1142.     CrossRef
SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways
Soo-Jin Oh , Ok Sarah Shin
J. Microbiol. 2022;60(3):290-299.   Published online February 5, 2022
DOI: https://doi.org/10.1007/s12275-022-1525-1
  • 63 View
  • 0 Download
  • 15 Web of Science
  • 16 Crossref
AbstractAbstract
With global expansion of the COVID-19 pandemic and the emergence of new variants, extensive efforts have been made to develop highly effective antiviral drugs and vaccines against SARS-CoV-2. The interactions of coronaviruses with host antiviral interferon pathways ultimately determine successful viral replication and SARS-CoV-2-induced pathogenesis. Innate immune receptors play an essential role in host defense against SARS-CoV-2 via the induction of IFN production and signaling. Here, we summarize the recent advances in innate immune sensing mechanisms of SARS-CoV-2 and various strategies by which SARS-CoV-2 antagonizes antiviral innate immune signaling pathways, with a particular focus on mechanisms utilized by multiple SARS-CoV-2 proteins to evade interferon induction and signaling in host cell. Understanding the underlying immune evasion mechanisms of SARS-CoV-2 is essential for the improvement of vaccines and therapeutic strategies.

Citations

Citations to this article as recorded by  
  • Overview of the SARS-CoV-2 nucleocapsid protein
    Ahmed Eltayeb, Faisal Al-Sarraj, Mona Alharbi, Raed Albiheyri, Ehab Mattar, Isam M. Abu Zeid, Thamer A. Bouback, Atif Bamagoos, Bassam O. Aljohny, Vladimir N. Uversky, Elrashdy M. Redwan
    International Journal of Biological Macromolecules.2024; 260: 129523.     CrossRef
  • Does SARS-CoV-2 Induce IgG4 Synthesis to Evade the Immune System?
    Alberto Rubio-Casillas, Elrashdy Redwan, Vladimir Uversky
    Biomolecules.2023; 13(9): 1338.     CrossRef
  • Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations
    Marjahan Akhtar, Md. Rashedul Islam, Fatema Khaton, Umma Hany Soltana, Syeda Anoushka Jafrin, Sadia Isfat Ara Rahman, Imam Tauheed, Tasnuva Ahmed, Ishtiakul Islam Khan, Afroza Akter, Zahid Hasan Khan, Md. Taufiqul Islam, Farhana Khanam, Prasanta Kumar Bis
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier
    Aileen Faist, Sebastian Schloer, Angeles Mecate-Zambrano, Josua Janowski, André Schreiber, Yvonne Boergeling, Beate C.G. Conrad, Sriram Kumar, Leonie Toebben, Klaus Schughart, Morris Baumgardt, Mirjana Kessler, Katja Hoenzke, Andreas Hocke, Marcel Trautma
    Antiviral Research.2023; 209: 105475.     CrossRef
  • Serum neutralization of SARS‐CoV‐2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld
    Qianqian Zhao, Xin Wang, Ze Zhang, Xuefei Liu, Ping Wang, Jin Cao, Qiming Liang, Jieming Qu, Min Zhou
    Journal of Medical Virology.2023;[Epub]     CrossRef
  • IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein
    Vladimir Uversky, Elrashdy Redwan, William Makis, Alberto Rubio-Casillas
    Vaccines.2023; 11(5): 991.     CrossRef
  • Warmer ambient air temperatures reduce nasal turbinate and brain infection, but increase lung inflammation in the K18-hACE2 mouse model of COVID-19
    Troy Dumenil, Thuy T. Le, Daniel J. Rawle, Kexin Yan, Bing Tang, Wilson Nguyen, Cameron Bishop, Andreas Suhrbier
    Science of The Total Environment.2023; 859: 160163.     CrossRef
  • Dexamethasone impairs the expression of antimicrobial mediators in lipopolysaccharide-activated primary macrophages by inhibiting both expression and function of interferon β
    John D. O’Neil, Oliwia O. Bolimowska, Sally A. Clayton, Tina Tang, Kalbinder K. Daley, Samuel Lara-Reyna, Jordan Warner, Claire S. Martin, Rahul Y. Mahida, Rowan S. Hardy, J. Simon C. Arthur, Andrew R. Clark
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Selenoprotein S Interacts with the Replication and Transcription Complex of SARS-CoV-2 by Binding nsp7
    Farid Ghelichkhani, Fabio A. Gonzalez, Mariia A. Kapitonova, Sharon Rozovsky
    Journal of Molecular Biology.2023; 435(8): 168008.     CrossRef
  • Pathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas
    Zaid Khreefa, Mallory T. Barbier, Ali Riza Koksal, Gordon Love, Luis Del Valle
    Cells.2023; 12(2): 262.     CrossRef
  • Selenoprotein S: A versatile disordered protein
    Farid Ghelichkhani, Fabio A. Gonzalez, Mariia A. Kapitonova, Stephanie Schaefer-Ramadan, Jun Liu, Rujin Cheng, Sharon Rozovsky
    Archives of Biochemistry and Biophysics.2022; 731: 109427.     CrossRef
  • Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19
    Agustín Valenzuela-Fernández, Romina Cabrera-Rodriguez, Laura Ciuffreda, Silvia Perez-Yanes, Judith Estevez-Herrera, Rafaela González-Montelongo, Julia Alcoba-Florez, Rodrigo Trujillo-González, Diego García-Martínez de Artola, Helena Gil-Campesino, Oscar
    Frontiers in Bioengineering and Biotechnology.2022;[Epub]     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
  • Warmer Ambient Air Temperatures Reduce Nasal Turbinate and Brain Infection, But Increase Lung Inflammation in the K18-hACE2 Mouse Model of COVID-19
    Troy Dumenil, Thuy T. Le, Daniel Rawle, Kexin Yan, Bing Tang, Wilson Nguyen, Cameron Bishop, Andreas Suhrbier
    SSRN Electronic Journal.2022;[Epub]     CrossRef
  • SARS-CoV-2: A Master of Immune Evasion
    Alberto Rubio-Casillas, Elrashdy M. Redwan, Vladimir N. Uversky
    Biomedicines.2022; 10(6): 1339.     CrossRef
  • Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study
    Nan Xu, Jinjin Pan, Li Sun, Cuimei Zhou, Siran Huang, Mingwei Chen, Junfei Zhang, Tiantian Zhu, Jiabin Li, Hong Zhang, Yufeng Gao
    Frontiers in Immunology.2022;[Epub]     CrossRef
Coordinated regulation of interferon and inflammasome signaling pathways by SARS-CoV-2 proteins
Na-Eun Kim , Yoon-Jae Song
J. Microbiol. 2022;60(3):300-307.   Published online January 28, 2022
DOI: https://doi.org/10.1007/s12275-022-1502-8
  • 58 View
  • 0 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract
Type I and III interferons (IFNs) and the nucleotide-binding domain (NBD) leucine-rich repeat (LRR)-containing receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome play pivotal roles in the pathogenesis of SARS-CoV-2. While optimal IFN and inflammasome responses are essential for limiting SARS-CoV-2 infection, aberrant activation of these innate immune responses is associated with COVID-19 pathogenesis. In this review, we focus our discussion on recent findings on SARS-CoV-2-induced type I and III IFNs and NLRP3 inflammasome responses and the viral proteins regulating these mechanisms.

Citations

Citations to this article as recorded by  
  • The impact of polymorphic variants of interferon receptor genes on COVID-19 severity and antibiotic resistance
    E. A. Krieger, O. V. Samodova, O. A. Svitich, R. V. Samoilikov, E. A. Meremianina, L. V. Ivanova, N. A. Bebyakova, E. N. Ilina, A. V. Pavlenko, Yu. I. Esin, A. L. Arkhipova, S. N. Kovalchuk, A. V. Kudryavtsev
    Russian Journal of Infection and Immunity.2024; 13(6): 1027.     CrossRef
  • SARS-CoV-2 ORF8 as a Modulator of Cytokine Induction: Evidence and Search for Molecular Mechanisms
    Marília Inês Móvio, Giovana Waner Carneiro de Almeida, Isabella das Graças Lopes Martines, Gilmara Barros de Lima, Sergio Daishi Sasaki, Alexandre Hiroaki Kihara, Emma Poole, Michael Nevels, Maria Cristina Carlan da Silva
    Viruses.2024; 16(1): 161.     CrossRef
  • Sensing of viral lung infections by cGAS-STING
    Lei Fang, Michael Roth
    Exploration of Immunology.2022; : 303.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
  • The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2
    Davide Ferrari, Michele Rubini, Jorge S. Burns
    Frontiers in Immunology.2022;[Epub]     CrossRef
Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines
Heedo Park , Mee Sook Park , Jong Hyeon Seok , Jaehwan You , Jineui Kim , Jeonghun Kim , Man-Seong Park
J. Microbiol. 2022;60(3):308-320.   Published online March 2, 2022
DOI: https://doi.org/10.1007/s12275-022-1598-x
  • 56 View
  • 0 Download
  • 5 Web of Science
  • 6 Crossref
AbstractAbstract
The three types of approved coronavirus disease 2019 (COVID- 19) vaccines that have been emergency-use listed (EUL) by the World Health Organization are mRNA vaccines, adenovirus- vectored vaccines, and inactivated vaccines. Canonical vaccine developments usually take years or decades to be completed to commercialization; however, the EUL vaccines being used in the current situation comprise several COVID- 19 vaccine candidates applied in studies and clinical settings across the world. The extraordinary circumstances of the COVID-19 pandemic have necessitated the emergency authorization of these EUL vaccines, which have been rapidly developed. Although the benefits of the EUL vaccines outweigh their adverse effects, there have been reports of rare but fatal cases directly associated with COVID-19 vaccinations. Thus, a reassessment of the immunological rationale underlying EUL vaccines in relation to COVID-19 caused by SARSCOV- 2 virus infection is now required. In this review, we discuss the manifestations of COVID-19, immunologically projected effects of EUL vaccines, reported immune responses, informed issues related to COVID-19 vaccination, and the potential strategies for future vaccine use against antigenic variants.

Citations

Citations to this article as recorded by  
  • Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron variants of concern
    Evgeny B. Faizuloev, Anastasiia V. Gracheva, Ekaterina R. Korchevaya, Yulia I. Ammour, Daria I. Smirnova, Darya M. Khokhlova, Andrey O. Drokov, Andrey A. Pankratov, Galina V. Trunova, Varvara A. Khokhlova, Maria S. Vorontsova, Irina A. Leneva, Oksana A. S
    Journal of microbiology, epidemiology and immunobiology.2024; 101(1): 36.     CrossRef
  • Real-time infectious disease endurance indicator system for scientific decisions using machine learning and rapid data processing
    Shivendra Dubey, Dinesh Kumar Verma, Mahesh Kumar
    PeerJ Computer Science.2024; 10: e2062.     CrossRef
  • A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients
    Sikai Chen, Wenxin Wei, Fengyu Huang, Jing Wang, Xingyu Li, Zhixin Geng, Feng Gao, Taiwei Dong, Peifeng Wei, Xinbo Yang, Feng Miao
    Human Vaccines & Immunotherapeutics.2023;[Epub]     CrossRef
  • Extracellular Vesicle-Based SARS-CoV-2 Vaccine
    Yasunari Matsuzaka, Ryu Yashiro
    Vaccines.2023; 11(3): 539.     CrossRef
  • Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences
    Dorota Kamińska, Dominika Dęborska-Materkowska, Katarzyna Kościelska-Kasprzak, Oktawia Mazanowska, Agata Remiorz, Paweł Poznański, Magdalena Durlik, Magdalena Krajewska
    Vaccines.2022; 10(7): 1068.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity
Mi-Hyun Lee , Bum-Joon Kim
J. Microbiol. 2022;60(3):321-334.   Published online February 14, 2022
DOI: https://doi.org/10.1007/s12275-022-1621-2
  • 60 View
  • 0 Download
  • 11 Web of Science
  • 13 Crossref
AbstractAbstract
Severe acute respiratory syndrome coronavirus 2 virus (SARSCoV- 2) infection, which causes coronavirus disease 2019 (COVID-19), has led to many cases and deaths worldwide. Therefore, a number of vaccine candidates have been developed to control the COVID-19 pandemic. Of these, to date, 21 vaccines have received emergency approval for human use in at least one country. However, the recent global emergence of SARS-CoV-2 variants has compromised the efficacy of the currently available vaccines. To protect against these variants, the use of vaccines that modulate T cell-mediated immune responses or innate immune cell memory function, termed trained immunity, is needed. The major advantage of a vaccine that uses bacteria or viral systems for the delivery of COVID-19 antigens is the ability to induce both T cell-mediated and humoral immune responses. In addition, such vaccine systems can also exert off-target effects via the vector itself, mediated partly through trained immunity; compared to other vaccine platforms, suggesting that this approach can provide better protection against even vaccine escape variants. This review presents the current status of the development of COVID-19 vaccines based on recombinant viral and bacterial delivery systems. We also discuss the current status of the use of licensed live vaccines for other infections, including BCG, oral polio and MMR vaccines, to prevent COVID-19 infections.

Citations

Citations to this article as recorded by  
  • Real-time infectious disease endurance indicator system for scientific decisions using machine learning and rapid data processing
    Shivendra Dubey, Dinesh Kumar Verma, Mahesh Kumar
    PeerJ Computer Science.2024; 10: e2062.     CrossRef
  • What is the role of microbial biotechnology and genetic engineering in medicine?
    Fernando Santos‐Beneit
    MicrobiologyOpen.2024;[Epub]     CrossRef
  • Previous BCG vaccination is associated with less severe clinical progression of COVID-19
    Susan Martins Pereira, Florisneide Rodrigues Barreto, Ramon Andrade de Souza, Carlos Antonio de Souza Teles Santos, Marcos Pereira, Enny Santos da Paixão, Carla Cristina Oliveira de Jesus Lima, Marcio Santos da Natividade, Ana Angélica Bulcão Portela Lind
    BMC Medicine.2023;[Epub]     CrossRef
  • COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type
    Areg A. Totolian, Viacheslav S. Smirnov, Alexei A. Krasnov, Edward S. Ramsay, Vladimir G. Dedkov, Anna Y. Popova
    Viruses.2023; 15(11): 2181.     CrossRef
  • The Cellular and Epigenetic Aspects of Trained Immunity and Prospects for Creation of Universal Vaccines on the Eve of More Frequent Pandemics
    I. V. Alekseenko, R. G. Vasilov, L. G. Kondratyeva, S. V. Kostrov, I. P. Chernov, E. D. Sverdlov
    Russian Journal of Genetics.2023; 59(9): 851.     CrossRef
  • Coronavirus XBB.1.5 as an Indicator of the Long-Term Continuation of the Covid-19 pandemic. What Next for Vaccination?
    E. P. Kharchenko
    Epidemiology and Vaccinal Prevention.2023; 22(2): 12.     CrossRef
  • Extracellular Vesicle-Based SARS-CoV-2 Vaccine
    Yasunari Matsuzaka, Ryu Yashiro
    Vaccines.2023; 11(3): 539.     CrossRef
  • Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
    Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
    Journal of Microbiology and Biotechnology.2023; 33(12): 1587.     CrossRef
  • Leishmania tarentolae: a vaccine platform to target dendritic cells and a surrogate pathogen for next generation vaccine research in leishmaniases and viral infections
    Claudio Bandi, Jairo Alfonso Mendoza-Roldan, Domenico Otranto, Alessandro Alvaro, Viviane Noll Louzada-Flores, Massimo Pajoro, Ilaria Varotto-Boccazzi, Matteo Brilli, Alessandro Manenti, Emanuele Montomoli, Gianvincenzo Zuccotti, Sara Epis
    Parasites & Vectors.2023;[Epub]     CrossRef
  • Cellular and Epigenetic Aspects of Trained Immunity and Prospects for Creation of Universal Vaccines in the Face of Increasingly Frequent Pandemics
    I. V. Alekseenko, R. G. Vasilov, L. G. Kondratyeva, S. V. Kostrov, I. P. Chernov, E. D. Sverdlov
    Генетика.2023; 59(9): 981.     CrossRef
  • BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists
    Andrés Noé, Thanh D. Dang, Christine Axelrad, Emma Burrell, Susie Germano, Sonja Elia, David Burgner, Kirsten P. Perrett, Nigel Curtis, Nicole L. Messina
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • The Natural Effect of BCG Vaccination on COVID-19: The Debate Continues
    Wenping Gong, Huiru An, Jie Wang, Peng Cheng, Yong Qi
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2
Chulwoo Kim , Jae-Deog Kim , Sang-Uk Seo
J. Microbiol. 2022;60(3):335-346.   Published online January 28, 2022
DOI: https://doi.org/10.1007/s12275-022-1608-z
  • 67 View
  • 0 Download
  • 25 Web of Science
  • 24 Crossref
AbstractAbstract
The global spread of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has provoked an urgent need for prophylactic measures. Several innovative vaccine platforms have been introduced and billions of vaccine doses have been administered worldwide. To enable the creation of safer and more effective vaccines, additional platforms are under development. These include the use of nanoparticle (NP) and virus-like particle (VLP) technology. NP vaccines utilize self-assembling scaffold structures designed to load the entire spike protein or receptor-binding domain of SARS-CoV-2 in a trimeric configuration. In contrast, VLP vaccines are genetically modified recombinant viruses that are considered safe, as they are generally replication-defective. Furthermore, VLPs have indigenous immunogenic potential due to their microbial origin. Importantly, NP and VLP vaccines have shown stronger immunogenicity with greater protection by mimicking the physicochemical characteristics of SARS-CoV-2. The study of NPand VLP-based coronavirus vaccines will help ensure the development of rapid-response technology against SARS-CoV-2 variants and future coronavirus pandemics.

Citations

Citations to this article as recorded by  
  • Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants
    Yue Xi, Rongrong Ma, Shuo Li, Gang Liu, Chao Liu
    Vaccines.2024; 12(7): 764.     CrossRef
  • Biomimetic virus-like particles with magnetic core. From bioactivity to an immunodiagnostic tool
    Adam A. Mieloch, Anna M. Mleczko, Anna Samelak-Czajka, Paulina Jackowiak, Jakub D. Rybka
    Chemical Engineering Journal.2024; 485: 149714.     CrossRef
  • The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2
    Yuan Hu, Lili Liu, Shenghua Zhang, Shaoyu Su, Xiao Liang
    ACS Omega.2024; 9(5): 5175.     CrossRef
  • Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam
    Hai Trong Nguyen, Darryl Falzarano, Volker Gerdts, Qiang Liu, Leonidas Stamatatos
    Microbiology Spectrum.2024;[Epub]     CrossRef
  • Engineering Escherichia coli-Derived Nanoparticles for Vaccine Development
    Shubing Tang, Chen Zhao, Xianchao Zhu
    Vaccines.2024; 12(11): 1287.     CrossRef
  • A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates
    Yuanyuan Li, Siyu Tian, Yuanbao Ai, Zhulong Hu, Chao Ma, Meijuan Fu, Zhenqian Xu, Yan Li, Shuyun Liu, Yongjuan Zou, Yu Zhou, Jing Jin
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Design and Application of Biosafe Coronavirus Engineering Systems without Virulence
    Guoqiang Wu, Qiaoyu Li, Junbiao Dai, Guobin Mao, Yingxin Ma
    Viruses.2024; 16(5): 659.     CrossRef
  • From Sequence to System: Enhancing IVT mRNA Vaccine Effectiveness through Cutting-Edge Technologies
    Lifeng Xu, Chao Li, Rui Liao, Qin Xiao, Xiaoran Wang, Zhuo Zhao, Weijun Zhang, Xiaoyan Ding, Yuxue Cao, Larry Cai, Joseph Rosenecker, Shan Guan, Jie Tang
    Molecular Pharmaceutics.2024;[Epub]     CrossRef
  • Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections
    Mei Ren, Sahibzada Waheed Abdullah, Chenchen Pei, Huichen Guo, Shiqi Sun
    Veterinary Research.2024;[Epub]     CrossRef
  • Nanovaccines to combat drug resistance: the next-generation immunisation
    K. Manju, S. Niranjan Raj, H. K. Ranjini, S. Chandra Nayaka, P. Ashwini, S. Satish, M. N. Nagendra Prasad, Raghuraj Singh Chouhan, Syed Baker
    Future Journal of Pharmaceutical Sciences.2023;[Epub]     CrossRef
  • Multivalent vaccines against new SARS-CoV-2 hybrid variants
    Kiarash Ghazvini, Masoud Keikha
    Vacunas.2023; 24(1): 76.     CrossRef
  • Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
    Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
    Journal of Microbiology and Biotechnology.2023; 33(12): 1587.     CrossRef
  • The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop
    Heidi Hempel, Nicholas Mantis, Christopher D. Heaney, Ligia A. Pinto
    Human Vaccines & Immunotherapeutics.2023;[Epub]     CrossRef
  • Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases
    Sareh Kakavandi, Iman Zare, Maryam VaezJalali, Masoud Dadashi, Maryam Azarian, Abdullatif Akbari, Marzieh Ramezani Farani, Hamidreza Zalpoor, Bahareh Hajikhani
    Cell Communication and Signaling.2023;[Epub]     CrossRef
  • Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2
    Maluta Steven Mufamadi, Mpho Phehello Ngoepe, Ofentse Nobela, Nhlanhla Maluleke, Bafedile Phorah, Banele Methula, Thapelo Maseko, Dipuo Ingrid Masebe, Hazel Tumelo Mufhandu, Lebogang Maureen Katata-Seru, Claudio Acuña-Castillo
    BioMed Research International.2023;[Epub]     CrossRef
  • Current progress in the development of prophylactic and therapeutic vaccines
    Tingting Li, Ciying Qian, Ying Gu, Jun Zhang, Shaowei Li, Ningshao Xia
    Science China Life Sciences.2023; 66(4): 679.     CrossRef
  • Multivalent vaccines against new SARS-CoV-2 hybrid variants
    Kiarash Ghazvini, Masoud Keikha
    Vacunas (English Edition).2023; 24(1): 76.     CrossRef
  • Post‐Assembly Modification of Protein Cages by Ubc9‐Mediated Lysine Acylation
    Mikail D. Levasseur, Raphael Hofmann, Thomas G. W. Edwardson, Svenja Hehn, Manutsawee Thanaburakorn, Jeffrey W. Bode, Donald Hilvert
    ChemBioChem.2022;[Epub]     CrossRef
  • An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice
    Linda van Oosten, Kexin Yan, Daniel J. Rawle, Thuy T. Le, Jort J. Altenburg, Cyrielle Fougeroux, Louise Goksøyr, Willem Adriaan de Jongh, Morten A. Nielsen, Adam F. Sander, Gorben P. Pijlman, Andreas Suhrbier, Mark T. Heise
    Journal of Virology.2022;[Epub]     CrossRef
  • Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein
    Yong-Fei Zhou, Jiao-Jiao Nie, Chao Shi, Ke Ning, Yu-Feng Cao, Yanbo Xie, Hongyu Xiang, Qiuhong Xie
    Journal of Microbiology and Biotechnology.2022; 32(10): 1335.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
  • Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins
    Jing Chen, Wang Xu, Letian Li, Lichao Yi, Yuhang Jiang, Pengfei Hao, Zhiqiang Xu, Wancheng Zou, Peiheng Li, Zihan Gao, Mingyao Tian, Ningyi Jin, Linzhu Ren, Chang Li
    Frontiers in Cellular and Infection Microbiology.2022;[Epub]     CrossRef
  • Construction, Characterization, and Application of a Nonpathogenic Virus-like Model for SARS-CoV-2 Nucleocapsid Protein by Phage Display
    Yuting Wu, Bing Liu, Zhiwei Liu, Pengjie Zhang, Xihui Mu, Zhaoyang Tong
    Toxins.2022; 14(10): 683.     CrossRef
  • Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases
    Ejuan Zhang, Zhiyong Ma, Mengji Lu
    Cellular and Molecular Life Sciences.2022;[Epub]     CrossRef
Coronavirus enzyme inhibitors-experimentally proven natural compounds from plants
Junsoo Park , Rackhyun Park , Minsu Jang , Yea-In Park , Yeonjeong Park
J. Microbiol. 2022;60(3):347-354.   Published online January 28, 2022
DOI: https://doi.org/10.1007/s12275-022-1499-z
  • 55 View
  • 0 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract
Coronavirus disease (COVID-19) can cause critical conditions that require efficient therapeutics. Several medicines are derived from plants, and researchers are seeking natural compounds to ameliorate the symptoms of COVID-19. Viral enzymes are popular targets of antiviral medicines; the genome of coronaviruses encodes several enzymes, including RNAdependent RNA polymerase and viral proteases. Various screening systems have been developed to identify potential inhibitors. In this review, we describe the natural compounds that have been shown to exert inhibitory effects on coronavirus enzymes. Although computer-aided molecular structural studies have predicted several antiviral compound candidates, the current review focuses on experimentally proven natural compounds.

Citations

Citations to this article as recorded by  
  • Eupatin, a Flavonoid, Inhibits Coronavirus 3CL Protease and Replication
    Yea-In Park, Jang Hoon Kim, Siyun Lee, Ik Soo Lee, Junsoo Park
    International Journal of Molecular Sciences.2023; 24(11): 9211.     CrossRef
  • Structural Insights into Plasticity and Discovery of Flavonoid Allosteric Inhibitors of Flavivirus NS2B–NS3 Protease
    Marielena Vogel Saivish, Gabriela de Lima Menezes, Vivaldo Gomes da Costa, Liliane Nebo, Gislaine Celestino Dutra da Silva, Carolina Colombelli Pacca, Rafael Elias Marques, Maurício Lacerda Nogueira, Roosevelt Alves Da Silva
    Biophysica.2023; 3(1): 71.     CrossRef
  • Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19
    Corbin England, Jonathan TrejoMartinez, Paula PerezSanchez, Uddhab Karki, Jianfeng Xu
    Life.2023; 13(3): 617.     CrossRef
  • Computational investigation of natural compounds as potential main protease (Mpro) inhibitors for SARS-CoV-2 virus
    Chirag N. Patel, Siddhi P. Jani, Sivakumar Prasanth Kumar, Krunal M. Modi, Yogesh Kumar
    Computers in Biology and Medicine.2022; 151: 106318.     CrossRef
  • Two years of COVID-19 pandemic: where are we now?
    Jinjong Myoung
    Journal of Microbiology.2022; 60(3): 235.     CrossRef
  • Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity
    Chang Liu, Tess Puopolo, Huifang Li, Ang Cai, Navindra P. Seeram, Hang Ma
    Molecules.2022; 27(18): 6127.     CrossRef
  • Computational Approaches in the Discovery and Development of Therapeutic and Prophylactic Agents for Viral Diseases
    Anand Gaurav, Neetu Agrawal, Mayasah Al-Nema, Vertika Gautam
    Current Topics in Medicinal Chemistry.2022; 22(26): 2190.     CrossRef

Journal of Microbiology : Journal of Microbiology
TOP